Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 6/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931085 | 1.00 | DPP4 (0.38) | DPP4BACE1HDAC4SLC6A4SLC6A3 | |
| SCHEMBL2620046 | 1.00 | DPP4 (0.38) | DPP4BACE1HDAC4SLC6A4SLC6A3 | |
| SCHEMBL2931088 | 1.00 | DPP4 (0.38) | DPP4BACE1HDAC4SLC6A4SLC6A3 | |
| SCHEMBL8028570 | 0.87 | BACE1 (0.33) | DPP4BACE1 | |
| SCHEMBL2619844 | 0.87 | BACE1 (0.33) | DPP4BACE1 | |
| SCHEMBL8031667 | 0.87 | BACE1 (0.33) | DPP4BACE1 | |
| SCHEMBL2619846 | 0.87 | BACE1 (0.33) | DPP4BACE1 | |
| SCHEMBL2926455 | 0.87 | BACE1 (0.33) | DPP4BACE1 | |
| SCHEMBL16976815 | 0.85 | DPP4 (0.36) | DPP4BACE1HDAC4 | |
| SCHEMBL2619927 | 0.78 | KDM1A (0.35) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233474-B1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946210-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946211-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2233474-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203741-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | DPP4 926/4885BACE1 1/4885HDAC4 2401/4885 |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | DPP4 926/4885BACE1 1/4885HDAC4 2401/4885 |
| US-20120094984-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | DPP4 926/4885BACE1 1/4885HDAC4 2401/4885 |
| US-20100317850-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, APP, BACE2 | DPP4 1310/4885BACE1 1/4885HDAC4 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.